Last reviewed · How we verify

Tranexamic acid + Standard of Care

Pfizer · FDA-approved active Small molecule

Tranexamic acid + Standard of Care is a Antifibrinolytic agent Small molecule drug developed by Pfizer. It is currently FDA-approved for Reduction of blood loss in surgical procedures, Treatment of acute hemorrhage in trauma, Prevention of excessive bleeding in perioperative settings.

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, reducing blood loss in surgical and trauma settings when combined with standard care.

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, reducing blood loss in surgical and trauma settings when combined with standard care. Used for Reduction of blood loss in surgical procedures, Treatment of acute hemorrhage in trauma, Prevention of excessive bleeding in perioperative settings.

At a glance

Generic nameTranexamic acid + Standard of Care
SponsorPfizer
Drug classAntifibrinolytic agent
TargetPlasminogen / Plasmin
ModalitySmall molecule
Therapeutic areaHematology / Surgery / Trauma
PhaseFDA-approved

Mechanism of action

Tranexamic acid is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. By stabilizing clot formation, it reduces excessive bleeding in perioperative and acute hemorrhage contexts. When used as an adjunct to standard of care protocols, it decreases transfusion requirements and improves hemostatic outcomes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tranexamic acid + Standard of Care

What is Tranexamic acid + Standard of Care?

Tranexamic acid + Standard of Care is a Antifibrinolytic agent drug developed by Pfizer, indicated for Reduction of blood loss in surgical procedures, Treatment of acute hemorrhage in trauma, Prevention of excessive bleeding in perioperative settings.

How does Tranexamic acid + Standard of Care work?

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, reducing blood loss in surgical and trauma settings when combined with standard care.

What is Tranexamic acid + Standard of Care used for?

Tranexamic acid + Standard of Care is indicated for Reduction of blood loss in surgical procedures, Treatment of acute hemorrhage in trauma, Prevention of excessive bleeding in perioperative settings.

Who makes Tranexamic acid + Standard of Care?

Tranexamic acid + Standard of Care is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What drug class is Tranexamic acid + Standard of Care in?

Tranexamic acid + Standard of Care belongs to the Antifibrinolytic agent class. See all Antifibrinolytic agent drugs at /class/antifibrinolytic-agent.

What development phase is Tranexamic acid + Standard of Care in?

Tranexamic acid + Standard of Care is FDA-approved (marketed).

What are the side effects of Tranexamic acid + Standard of Care?

Common side effects of Tranexamic acid + Standard of Care include Thromboembolic events (deep vein thrombosis, pulmonary embolism), Seizures, Visual disturbances, Gastrointestinal disturbances, Hypotension.

What does Tranexamic acid + Standard of Care target?

Tranexamic acid + Standard of Care targets Plasminogen / Plasmin and is a Antifibrinolytic agent.

Related